Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Menen – page 116

1 845 clinical trials in Menen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Menen at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Menen

Open in trial search

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of Vidutolimod and Cemiplimab for Adults with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not recruiting

Study on Methotrexate and Glucocorticoid Combination for Early Rheumatoid Arthritis, with Optional Etanercept for Non-Responders

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:UZ Leuven

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Long-term Safety and Effects of ARGX-117 for Adults with Multifocal Motor Neuropathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Alagille syndrome

Not recruiting

Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Menen

What the registry says about research in the country

01 Advanced Lung Cancer Research

Investigating innovative treatments for Non-Small Cell Lung Cancer (NSCLC), with a focus on patients carrying specific genetic mutations like EGFR Exon 20 insertions. The research evaluates combination therapies using zipalertinib with traditional chemotherapy to improve treatment outcomes.

  • Targeted Therapy Development
  • Genetic Mutation Analysis
  • Combination Treatment Strategies

Studies aim to determine optimal dosing and measure progression-free survival rates in advanced cases.

02 Immunotherapy Research

Evaluating the effectiveness of therapeutic cancer vaccines compared to conventional chemotherapy in treating metastatic NSCLC patients. The research specifically focuses on patients with HLA-A2 positive phenotype who have experienced immunotherapy failure.

  • Cancer Vaccine Development
  • Treatment Resistance Studies
  • Overall Survival Analysis

Research aims to demonstrate improved survival outcomes using novel vaccine-based approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.